Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Shanghai Zai Lab Raises Hong Kong Listing to Primary Status

publication date: Jun 28, 2022

Shanghai Zai Lab has changed its Hong Kong listing from secondary listing status to primary listing. Zai says it now has dual-primary status in the US and Hong Kong. Zai is one of many China biopharmas that faces de-listing from a US exchange because of its financial auditor: China does not allow domestic companies to open their financial records to foreign auditors, but the US has will de-list any China company that does not allow US-certified auditors complete access to its financial data. A few months ago, China said it would change its rules, but so far no formal agreement has been announced. Zai seems to be taking the first protective steps against the US de-listing. More details....

Stock Symbol: (NSDQ: ZLAB; HK: 9688)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China